Metabolic health
GLP-1 heart and kidney benefits: match the label to the patient
Some GLP-1 products have approved cardiovascular or kidney-risk reduction indications. These benefits should be described precisely rather than attributed to every medicine in the class.
Cardiovascular indications differ
Wegovy's current label includes specified major cardiovascular-event risk reduction in an adult population with established cardiovascular disease and overweight or obesity. Ozempic has its own indication in adults with type 2 diabetes and established cardiovascular disease.
The August 2026 Mounjaro label also includes major adverse cardiovascular-event risk reduction in adults with type 2 diabetes at high risk. These are product-specific claims. Their eligibility and clinical role should not be collapsed into a statement that every GLP-1 prevents heart disease in every person.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information · Mounjaro prescribing information
Kidney benefit is not protection from dehydration
Ozempic is labeled to reduce the risk of sustained filtration decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. The label provides an indication-specific dosing recommendation.
That benefit coexists with a warning about acute kidney injury due to volume depletion. Vomiting or diarrhea can cause dehydration and needs assessment. A long-term risk-reduction indication does not make an acute adverse effect harmless.
Sources: Ozempic prescribing information
Continue the broader risk plan
A clinician should integrate medication choice with diabetes care, blood pressure, lipids, kidney assessment, and other established treatment needs. A GLP-1 prescription is not a reason to stop unrelated cardiovascular or kidney medicines on your own.
Ask how the diagnosis changes product choice, dose, follow-up, and insurance documentation. Changes in a laboratory marker are not automatically the same as a proven reduction in clinical events.
Sources: Ozempic prescribing information · Mounjaro prescribing information · Wegovy prescribing information, including tablets and Wegovy HD
Evidence does not transfer to a compounded formulation
Trials and indications concern specific approved medicines. A compounded product or an unstudied microdose cannot inherit the same cardiovascular or kidney claim because it uses similar ingredient language.
Ask a clinic to identify the product and the evidence behind any prevention claim. Distinguish an approved indication from a plausible mechanism, off-label clinical judgment, or marketing language.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.